Clinical trials: Head and Neck Cancers- Squamous Cell
Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma
PDT For Induction Therapy For Head And Neck Cancer
This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous…
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07214987
- Testing
- Toripalimab-tpzi, Cisplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06530914
- Testing
- MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin
- Volunteers
- 30 people
- Sponsor
- Lei Liu
Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC).
- Trial name
- NCT07137858
- Testing
- Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Squamous Cell Carcinoma of Head and Neck
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.
- Trial name
- NCT05845307
- Testing
- Control Group, TTI-101
- Sponsor
- M.D. Anderson Cancer Center
Bronchial Dysplasia, Tobacco Smoking
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the…
- Conditions
- Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
- Trial name
- NCT03347838
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort…
- Trial name
- NCT05674526
- Testing
- WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allotera Therapeutics
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Oral Cancer
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC).
- Trial name
- NCT00933387
- Testing
- Cetuximab,Paclitaxel,Cisplatin
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- National Health Research Institutes, Taiwan
HNSCC
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
The aim of the trial is to study the efficacy of adding concomitant chemotherapy (carboplatin/5FU) to Erbitux-radiotherapy in patients with locally advanced head and neck cancer.
- Trial name
- 2007-01 (NCT00609284)
- Testing
- cetuximab, Carboplatin, 5FU concomitant, Radiotherapy
- Where
- 5 sites in France
- Volunteers
- 406 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
- Trial name
- NCT06448026
- Testing
- Cemiplimab, Cetuximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Solid Tumor, Adult
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
This study will assess the safety and tolerability and pharmacokinetics of BH009 in patients with advanced head and neck squamous (non-nasopharyngeal) and ovarian cancer.
- Trial name
- NCT06232863
- Testing
- BH009
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Squamous Cell Carcinoma, Head and Neck Cancer
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the…
- Trial name
- NCT01161498
- Testing
- Talimogene Laherparepvec, Radiation, Cisplatin
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- BioVex Limited
Head and Neck Cancer
Altered and Conventional Fractionated Radiotherapy in Patients With Head and Neck Cancer
The aim of our study was to evaluate the value of two different altered fractionation schedules - hyperfractionation and accelerated fractionation with concomitant boost - in comparison with conventional fractionation in primary…
- Trial name
- NCT00291434
- Volunteers
- 152 people
- Sponsor
- Institute of Radiotherapy and Oncology, Macedonia
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 203 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Janssen Research & Development, LLC
Squamous Cell Carcinoma, Oropharyngeal Cancers
Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment
Patients who are undergoing radiation therapy on their head and/or neck, are highly likely to experience oral mucositis, which is inflammation and irritation of the mucus membranes in your mouth.
- Conditions
- Squamous Cell Carcinoma, Oropharyngeal Cancers, Nasopharyngeal Cancer, Hypopharyngeal Cancer
- Trial name
- TOPHAT (NCT07697287)
- Testing
- Gelclair Oral Mouth Rinse
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McMaster University
Esophageal Cancer
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
- Trial name
- NCT05182944
- Testing
- A：non-pCR patients, B：non-pCR patients, A：pCR patients
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Squamous Cell Carcinoma of the Oropharynx
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
Hypoxia imaging has not been studied extensively by combining PET and MRI data. Few studies performed the double imaging and none associated anatomopathology with it .
- Trial name
- HYPONECK (NCT04031534)
- Testing
- F-Miso PET scan coupled with MRI
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Centre Henri Becquerel
Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery.
- Trial name
- NCT06186609
- Testing
- PD-1 inhibitor 200mg per three to four weeks, for one year
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Nantong University
Head and Neck Squamous Cell Carcinoma
Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer
The purpose of this study is to evaluate the use of Transoral Robotic Surgery (TORS) to identify small oropharyngeal carcinomas.
- Trial name
- FIND (NCT03281499)
- Testing
- da Vinci Surgical System Model IS4000
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.